男性特发性膀胱过度活动症膀胱内A型肉毒毒素注射的疗效与并发症
该回顾性研究纳入146例难治性特发性膀胱过度活动症男性患者,接受膀胱内注射100 IU onabotulinumtoxinA。91例(62.3%)报告治疗反应,24例(16.4%)出现并发症,其中尿潴留19例(13%)。随访超过12个月的128例中88例(68.8%)停药。较高的膀胱出口梗阻指数是治疗反应率较低和并发症率较高的唯一预测因素。
要点
- 多数男性特发性OAB患者对膀胱内肉毒毒素注射有治疗反应,但大部分停药。
- 尿潴留是最常见并发症(13%,CD 2级)。
- 较高膀胱出口梗阻指数预测较低治疗反应和较高并发症率。
核心结论
- 多数男性特发性膀胱过度活动症患者膀胱内注射onabotulinumtoxinA后有治疗反应,但多数停药。
- 较高膀胱出口梗阻指数与较低治疗反应率和较高并发症率相关。
研究设计与样本
- 回顾性研究,纳入2007年起本科室接受膀胱内注射100 IU onabotulinumtoxinA的难治性特发性膀胱过度活动症男性患者,排除既往根治性前列腺切除术者。
- 共146例男性,平均年龄70.1±13.3岁。
主要发现
- 91例(62.3%)报告治疗反应(治疗获益量表评分1或2)。
- 共发现24例并发症(16.4%),包括尿潴留19例(13%,CD 2)、血尿2例(1.3%,CD 1)、尿路感染3例(2%,CD 2)。
- 随访超过12个月的128例中,88例(68.8%)在随访结束时已停药。
- 较高的膀胱出口梗阻指数是治疗反应率较低和并发症率较高的唯一预测因素。
关键数值与推荐
- 治疗反应定义为治疗获益量表评分1(明显改善)或2(改善)。
- 并发症按Clavien-Dindo分类。
- 治疗持续定义为末次访视时患者在过去12个月内接受过onabotulinumtoxinA注射。
临床怎么用
- 对男性特发性OAB患者,膀胱内onabotulinumtoxinA注射可考虑作为难治性病例的治疗选择。
- 治疗前应评估膀胱出口梗阻指数,高指数患者可能治疗反应较差且并发症风险较高。
- 需告知患者多数可能最终停药,尿潴留是常见并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to assess the treatment response, complications and treatment continuation after onabotulinumtoxinA injection in male patients. MATERIALS AND METHODS: We performed a retrospective study of men with refractory idiopathic overactive bladder treated with intradetrusor injection of 100 IU onabotulinumtoxinA since 2007 in our department. Patients with previous radical prostatectomy were excluded from analysis. The treatment response was assessed using a treatment benefit scale of 1-greatly improved, 2-improved, 3-not changed and 4-worse after treatment. A treatment benefit scale score of 1 or 2 was considered a treatment response. Complications were classified according to the CD (Clavien-Dindo) classification. Treatment was considered to have continued if at the last visit patients had received an onabotulinumtoxinA injection within the preceding 12 months. We performed univariate and multivariate analyses to assess factors predictive of the treatment response, complications and continuation on treatment. RESULTS: Of the 146 men with a mean ± SD age of 70.1 ± 13.3 years who were included in study 91 (62.3%) reported a response to treatment. A total of 24 complications (16.4%) were detected, including 19 cases (13%) of urinary retention (CD 2), 2 (1.3%) of hematuria (CD 1) and 3 (2%) of urinary infection (CD 2). Followup was more than 12 months in 128 patients, of whom 88 (68.8%) had discontinued treatment by the end of followup. A higher bladder outlet obstruction index was the only factor predicting a lower treatment response rate and a higher complication rate. CONCLUSIONS: Most male patients with idiopathic overactive bladder showed a treatment response after intradetrusor onabotulinumtoxinA injection. However, the majority discontinued treatment. A higher bladder outlet obstruction index was related to a lower treatment response and a higher complication rate.
引用
- Mateu Arrom L, Mayordomo Ferrer O, Sabiote Rubio L, et al. Treatment Response and Complications after Intradetrusor OnabotulinumtoxinA Injection in Male Patients with Idiopathic Overactive Bladder Syndrome. J Urol. 2019. PMID: 31479408. doi:10.1097/JU.0000000000000525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。